Menopause Meets Automated Insulin Delivery: Where Today’s Algorithms May Fall Short

Automated insulin delivery (AID) has transformed type 1 diabetes care, but can today's algorithms keep pace with menopause? For women with type 1 diabetes who are approaching or experiencing menopause, changing hormone levels may introduce new challenges in glucose management. Although AID systems can respond to changing glucose readings, they do not directly measure reproductive hormones. Consequently, clinicians face an important question: Are current algorithms sufficiently equipped to manage the metabolic changes of menopause?

Table of Contents

1. How Menopause May Affect Glucose Control in Type 1 Diabetes
2. Where AID Algorithms May Face Challenges During Menopause
3. What Research Reveals About Hormones and Insulin Needs
4. Managing Type 1 Diabetes During Menopause: Clinical Priorities
5. Conclusion
6. Frequently Asked Questions

How Menopause May Affect Glucose Control in Type 1 Diabetes

Menopause involves more than the end of menstrual periods. During perimenopause, estrogen and progesterone levels fluctuate before declining more consistently after menopause. These changes can affect insulin sensitivity, body fat distribution, sleep, and overall metabolic health.

For women with type 1 diabetes, these shifts may complicate glucose management. Declining estrogen may contribute to insulin resistance, while changing hormone levels can coincide with unpredictable glucose patterns. However, the effects differ considerably between individuals, making it difficult to predict how insulin requirements will change.

A 2025 narrative review examining menopause in women with type 1 diabetes identified important evidence gaps. Researchers noted that altered insulin requirements and glucose variability have been reported during this transition, yet dedicated clinical studies remain limited.

Furthermore, menopausal symptoms can complicate diabetes management in less obvious ways. Night sweats and disrupted sleep may affect daily routines, while hot flashes can resemble symptoms of hypoglycemia. As a result, patients may struggle to determine whether symptoms reflect hormonal changes, falling glucose levels, or both.

Continuous glucose monitoring (CGM) offers valuable information during these periods. Nevertheless, detecting changes does not automatically explain their cause. Clinicians must consider hormonal, behavioral, and treatment-related factors when interpreting glucose patterns.

Where AID Algorithms May Face Challenges During Menopause

Automated insulin delivery combines a continuous glucose monitor, an insulin pump, and software that adjusts insulin delivery based on glucose readings and other system inputs. Devices such as the MiniMed 780G, Tandem Control-IQ systems, and Omnipod 5 provide varying degrees of automated insulin adjustment.

These technologies have demonstrated meaningful improvements in glucose management. Indeed, the American Diabetes Association's 2026 Standards of Care identify AID as the preferred insulin delivery method for people with type 1 diabetes who can use the technology safely.

However, current systems do not directly identify menopause or measure estrogen and progesterone concentrations. Instead, they respond to glucose patterns, insulin delivery history, and other inputs supported by each device.

The Challenge of Changing Insulin Requirements

Consider a patient whose insulin needs change during perimenopause. Her AID system may respond to rising glucose concentrations by increasing insulin delivery. However, its response may not fully anticipate changes associated with sleep disturbances, altered physical activity, or shifting insulin sensitivity.

Additionally, insulin delivered beneath the skin takes time to act. Therefore, even sophisticated algorithms cannot immediately correct every unexpected glucose change. Hormonal changes may also occur alongside other influences, making it difficult to determine what caused a particular glucose pattern.

This represents a potential limitation rather than proof that AID performs poorly during menopause. Importantly, direct evidence comparing AID performance across menopausal stages remains insufficient.

For additional information about insulin delivery technologies and treatment advances, visit the Diabetes in Control Insulin Therapy Center.

What Research Reveals About Hormones and Insulin Needs

Research involving menstrual cycles offers useful clues about reproductive hormones and insulin requirements. However, menstrual cycle findings cannot automatically be applied to menopause.

A 2026 observational study published in Diabetes Care examined 77 individuals with type 1 diabetes using AID systems across 380 menstrual cycles. Researchers found changes in insulin sensitivity, daily insulin requirements, and glucose outcomes between cycle phases.

Notably, insulin requirements increased during the luteal phase, when time in range declined. The findings suggest that hormonal variation can influence glucose management even when automated insulin delivery is used.

Another 2026 observational study involving 17 women using the MiniMed 780G found lower time in range during the late luteal phase than during the early follicular phase. Specifically, time in range was 80.7% versus 82.7%, respectively. The study also identified higher insulin requirements during the late luteal phase.

Although these findings are relevant, they do not establish how menopause affects algorithm performance. Menstrual cycles involve recurring hormonal patterns, whereas menopause introduces a different and often less predictable hormonal transition.

Furthermore, research comparing AID outcomes specifically among premenopausal, perimenopausal, and postmenopausal women remains inadequate. Existing findings should therefore guide research questions rather than establish menopause-specific treatment recommendations.

Thus, the central question is not whether AID works, but whether its performance could improve through better recognition of hormone-related changes.

Managing Type 1 Diabetes During Menopause: Clinical Priorities

Until menopause-specific evidence becomes available, clinicians should emphasize individualized care rather than predetermined algorithm adjustments.

For women with type 1 diabetes experiencing changes in glucose control during menopause, reviewing CGM reports may help identify recurring patterns. Time in range, time below range, overnight glucose trends, and total daily insulin requirements offer useful starting points.

Additionally, clinicians should ask about hot flashes, sleep quality, menstrual changes, physical activity, and medication use. These factors may provide context for glucose changes that technology alone cannot explain.

Conversations about diabetes management should also address the patient's experience. For example, frequent glucose alerts, sleep disruption, and uncertainty about changing insulin needs may increase treatment burden. Recognizing these concerns can help clinicians develop more practical and sustainable care plans.

Individualized Care Without Unsupported Algorithm Changes

When glucose patterns change, clinicians can review meal bolusing, device settings, infusion-site issues, and the patient's daily routine. Any adjustments should reflect the individual's clinical needs and the capabilities of the specific AID system.

Furthermore, menopausal hormone therapy requires separate consideration. Evidence remains insufficient to recommend hormone therapy specifically to improve glycemic outcomes in women with type 1 diabetes. Decisions about treatment should instead consider menopausal symptoms, individual risks, and established clinical guidance.

Future clinical trials should include women at different menopausal stages and evaluate outcomes such as time in range, hypoglycemia, insulin requirements, and treatment burden.

Researchers should also investigate whether incorporating hormone-related information into future algorithms improves outcomes compared with existing adaptive systems. Such research could help determine whether personalized adjustments provide benefits beyond current automated responses.

Ultimately, these studies could support more personalized diabetes technology without assuming that every woman experiences identical hormonal or metabolic changes.

Conclusion

Automated insulin delivery remains an important advance in type 1 diabetes management. However, menopause introduces physiological changes that current algorithms may not fully anticipate.

Evidence from menstrual cycle research demonstrates that reproductive hormones can influence glucose regulation, but menopause-specific AID research remains limited. Consequently, clinicians should avoid assuming that findings from younger, menstruating populations apply directly to women undergoing menopause.

For now, clinicians should combine AID technology with careful CGM review, individualized treatment decisions, and attention to menopausal symptoms. Better research may eventually reveal whether algorithms need specific adaptations for this stage of life.

Frequently Asked Questions

Does menopause increase insulin resistance in women with type 1 diabetes?

Menopause may contribute to reduced insulin sensitivity through declining estrogen and changes in body composition. However, individual responses vary, and menopause-specific evidence in type 1 diabetes remains limited.

Can automated insulin delivery systems adjust to hormonal fluctuations?

AID systems can adjust insulin delivery in response to changing glucose readings. However, they do not directly measure reproductive hormones or identify menopausal stages. Their ability to respond to changing insulin needs depends on the system and the individual's glucose patterns.

Is automated insulin delivery recommended during menopause?

Yes. AID remains a recommended insulin delivery option for eligible people with type 1 diabetes. Menopause itself is not a reason to discontinue an effective system. Treatment decisions should reflect individual needs and clinical circumstances.

Should insulin pump settings change automatically during perimenopause?

No standard menopause-specific setting changes have been validated. Instead, clinicians should individualize adjustments using CGM patterns, clinical assessment, and device-specific guidance. Changes should account for the patient's glucose trends and risk of hypoglycemia.

What research is needed to improve diabetes technology during menopause?

Researchers need prospective studies comparing AID performance across menopausal stages. Such studies should examine insulin sensitivity, glucose variability, hypoglycemia, and whether hormone-aware algorithms offer measurable benefits over existing systems.

This content is not medical advice. For any health issues, always consult a healthcare professional. In an emergency, call 911 or your local emergency services.